AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies.
Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor therapies (TCR-Ts) to treat solid tumors. TCR-Ts are designed to recognize intracellular targets, including cancer-specific mutations, thus potentially unlocking targets previously inaccessible through cell therapies.
